Policy Forum

Treatment of Young Children with HIV Infection: Using Evidence to Inform Policymakers

Andrew J. Prendergast1-2,3*, Martina Penazzato2, Mark Cotton4, Philippa Musoke5, Veronica Mulenga6, Elaine J. Abrams7, Diana M. Gibb2

1 Centre for Paediatrics, Blizard Institute, Queen Mary University of London, London, United Kingdom, 2 MRC Clinical Trials Unit, London, United Kingdom, 3 Zvitambgo Project, Harare, Zimbabwe, 4 Children’s Infectious Disease Clinical Research Unit, Faculty of Health Sciences, Stellenbosch University and Tygerberg Children’s Hospital, Tygerberg, South Africa, 5 Mulago Hospital, Paediatric Infectious Diseases Clinic, Kampala, Uganda, 6 University Teaching Hospital, Lusaka, Zambia, 7 ICAP, Mailman School of Public Health and College of Physicians & Surgeons, Columbia University, New York, New York, United States of America

Despite efforts to scale up prevention of mother-to-child transmission (PMTCT) of HIV, over 1,000 infants continue to be infected daily, particularly in sub-Saharan Africa [1]. Disease progression in infants is much more rapid than in older children and adults, with mortality exceeding 50% by 2 years of age in the absence of antiretroviral therapy (ART) [2]. Although combination ART has been available since 1997, diagnosis and treatment of infants is much more challenging compared to older children and adults (Box 1). Furthermore, until recently there was little evidence to guide treatment approaches in infants and young children, with international policymakers relying on data from cohort studies and expert opinion to inform guidelines. In the past 5 years, results have emerged from several randomized clinical trials of children with HIV under 2 years of age (Table 1) [3–8]; a systematic review of these trials has just been published [9]. Here, we consider the implications of research findings for forthcoming World Health Organization (WHO) guidelines and, ultimately, for policymakers, who will need to weigh efficicacy and feasibility of interventions in their particular settings in low- and middle-income countries (LMIC).

When Should Antiretroviral Therapy Be Started in Young Children?

Several small, observational studies suggested a benefit to starting ART early in infants with HIV [10–12], but given the challenges of treatment at this age, together with lack of robust evidence, WHO, European, and United States treatment guidelines differed in their recommendations until 2007, when the Children with HIV Early Antiretroviral Therapy (CHER) trial provided definitive evidence of the need to start ART soon after birth [8]. Asymptomatic, immunologically intact infants with HIV recruited before 12 weeks of age were randomized to start ART either immediately, or once clinical or immunological recommended thresholds were reached. Infants starting immediate ART had a 4-fold reduction in mortality and disease progression compared to infants starting deferred ART (Table 1).

Although the CHER trial was conducted in South Africa, it changed policy in all settings, supported by observational data from Europe and the US [10–12]. Interim WHO guidance in 2008 recommended early treatment for infants (children under 1 year) in LMIC; in WHO 2010 guidelines, this recommendation was further extended to include all children under 2 years of age. This age extension was not supported by robust evidence of benefit from early treatment, in particular for infants under 1 year.

Citation: Prendergast AJ, Penazzato M, Cotton M, Musoke P, Mulenga V, et al. (2012) Treatment of Young Children with HIV Infection: Using Evidence to Inform Policymakers. PLoS Med 9(7): e1001273. doi:10.1371/journal.pmed.1001273

Published July 24, 2012

Copyright: © 2012 Prendergast et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: No specific funding was received for writing this article. The trial funders mentioned in this article had no role in the decision to publish or preparation of this manuscript.

Competing Interests: AP is a co-investigator on the PEHSS and ARROW trials but did not receive any funds for participation in these trials. MP has been supported by the European Union (EU; FP7) through the Paediatric-European Network for the Treatment of AIDS Foundation for the past three years and is currently working as a consultant for the HIV Department at the World Health Organization (WHO). MC was a co-investigator on the P1060 and CHER trials and funds for the P1060 trial contributed to MC's salary. MC is an investigator for the International Maternal Pediatric Adolescent AIDS Clinical Trial (IMPAACT) group, funded through the Division of AIDS (DAIDS), National Institute of Allergy & Infectious Diseases (NIAID). MC has been an investigator for pharmaceutical trials for BMS and GSK from 2008 to present; funds provide site support but no contribution to his salary. MC is a member of Essential Drug list committee for children in public hospitals (2008–2012) and the Paediatric Expert Group for National Department of Health and HIV Clinicians Society of Southern Africa. MC is a member of the WHO clinical task team for Antiretroviral guidelines; attended meetings from 2006 to 2008; and still contributes opinions by email. PM is a co-investigator on the ARROW trial and receives funding from DAIDS and MRC UK for this work. VM is an investigator on the CHAPAS 3 trial and receives a project management allowance for her work. VM is a member of the WHO Paediatric Antiretroviral Working Group (PAWG) committee; travel to a PAWG meeting was paid for by WHO in October 2011. EJA is a co-investigator on the P1060 and NEVEREST trials and funds from the NEVEREST trial contribute to EJA’s salary. EJA is an investigator for the IMPAACT group, funded through DAIDS, NIAID. EJA is Chair of the HIV Treatment Impact Committee, IMPAACT group. EJA receives partial salary support from NIAID for her role as Chair and medications for studies are generally donated. EJA is a member of the US Public Health Service (USPHS) guidelines committee for antiretroviral treatment of children and co-Chair of the WHO Antiretroviral Guidelines Committee. She receives no financial support for these activities. DMG is a co-investigator on the ARROW trial and receives funding from the MRC UK, DFID, ECDCP, and EU (FP7). DMG has been Chair of Data Monitoring Committees for industry paediatric trials undertaken by Tibotec (now finished). AP, MP, EJA, and DMG are members of the WHO paediatric ARV working group but receive no financial support for this activity.

Abbreviations: ART, antiretroviral therapy; CHER, Children with HIV Early Antiretroviral Therapy; EID, early infant diagnosis; FDC, fixed-dose combination; LMIC, low- and middle-income countries; LPV/r, lopinavir/ritonavir; NNRTI, non-nucleoside reverse transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor; PMTCT, prevention of mother-to-child transmission; WHO, World Health Organization

* E-mail: a.prendergast@qmul.ac.uk

Provenance: Not commissioned; externally peer reviewed.
Summary Points

- Early initiation of antiretroviral therapy (ART) in infants with HIV leads to a 4-fold reduction in mortality compared to deferred ART
- Young children starting a first-line ART regimen containing a non-nucleoside reverse transcriptase inhibitor (nevirapine; NVP) have a 2-fold higher risk of treatment failure than those who start a regimen containing a protease inhibitor (lopinavir/ritonavir; LPV/r)
- Use of LPV/r in infants is challenging due to its expense, unpalatable formulation, and potential long-term toxicity
- Better formulations of ART are urgently required for infants and young children

Table 1. Published randomized clinical trials evaluating treatment strategies in infants and young children with HIV.

| Question                                                                 | Trial Details                                                                 | Main Results                                                                 |
|-------------------------------------------------------------------------|-------------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| When should antiretroviral therapy be started in young children?        | • CHER (South Africa) [8]: 377 asymptomatic HIV-infected infants aged 6–12 weeks, with CD4 ≥25%, were randomized to 1) Immediate ART for 40 weeks; 2) Immediate ART for 96 weeks; 3) Deferred ART according to WHO criteria. First-line ART regimen comprised ZDV, 3TC, LPV/r. Primary outcomes: time to death or failure of first-line ART (defined as failure to reach CD4 ≥20% by week 24 of ART; decrease to CD4 <20% after week 24; progression to CDC severe stage B or stage C clinical events; toxicity requiring >1 drug substitution within the same class, a switch to a new class, or permanent discontinuation of treatment). • PEHSS (South Africa) [7]: 63 infants with HIV were enrolled at birth to a pilot feasibility study of early ART strategies, with randomization to: 1) Immediate ART for 1 year; 2) Immediate ART for 12–18 months with up to 3 structured treatment interruptions; 3) Deferred ART according to WHO criteria. First-line ART regimen comprised ZDV, 3TC, NVP, and NFV, with NVP discontinued once virological suppression (VL <50 copies/mL) achieved. Primary outcome: proportion of infants progressing to AIDS by 3 years of age (not yet reported). Clinical, virological, and immunological outcomes have been reported. | • After median follow-up of 40 weeks (IQR 24–58), mortality was 16% in the deferred ART group vs 4% in the early ART groups (p = 0.001). Early ART was associated with 76% reduction in mortality and 75% reduction in disease progression. The DSMB recommended early dissemination of these findings and urgent evaluation of untreated infants in the deferred group for possible initiation of ART. |
| Which antiretroviral therapy should be started in young children?        | P1060 (South Africa, Zimbabwe, Zambia, Malawi, Uganda, Tanzania, India) [5,6]: Two parallel trials of first-line treatment regimens in children below 3 years of age who qualified for ART by WHO criteria. Children in cohort 1 (n = 164) had previously been exposed to sd-NVP; children in cohort 2 (n = 288) had not previously been exposed to sd-NVP. Children were randomized to 1) ZDV, 3TC, NVP or 2) ZDV, 3TC, LPV/r. Primary outcome: Treatment failure by 24 weeks, defined as permanent discontinuation of the treatment regimen for any reason, including death, toxic effects, and virological failure (confirmed viral load <1 log₁₀ copies/mL below the study-entry level after 12–24 weeks, or confirmed viral load >400 copies/mL at 24 weeks). | • No significant difference in 12-month mortality between immediate (12%) and deferred (5%) groups (p = 0.65). However, study not designed or powered to address the question of when to start ART. Infants randomized to immediate compared to deferred ART had reduced morbidity (median 7 vs 12 illness episodes; p = 0.003), but similar virological and immunological response to ART. |
| Can antiretroviral therapy be switched in young children?                | NEVEREST (South Africa) [3,4]: 323 children under 2 years of age, previously exposed to sd-NVP, started a first-line ART regimen comprising d4T, 3TC, LPV/r. 195 infants who maintained viral load <400 copies/mL for ≥3 months were randomized to 1) continue LPV/r or 2) change to NVP. Primary outcome: Viral load >50 copies/mL at 52 weeks. Safety endpoint: Confirmed viral load >1,000 copies/mL. | In cohort 1, more children in the NVP group than the LPV/r group reached the primary endpoint of treatment failure at 24 weeks (39.6% vs 21.7%, respectively; p = 0.02). Similar results were seen in cohort 2 (40.1% vs 18.6%, for NVP vs LPV/r, respectively; p < 0.001). In meta-analysis, the hazard of treatment failure was 2.01 (95% CI 1.47, 2.77) times higher for children starting ART with an NVP-based regimen compared to a LPV/r-based regimen, with no heterogeneity across the two trials. Children changing to NVP, compared to those staying on LPV/r, had a lower hazard of VL ≥50 copies/mL (HR = 0.62, 95% CI 0.41, 0.92; p = 0.02), but a higher hazard of confirmed VL ≥1,000 copies/mL (HR = 10.19, 95% CI 2.36, 43.94; p = 0.002). Longer follow-up to 156 weeks confirmed these findings. |

ZDV, zidovudine; 3TC, lamivudine; NVP, nevirapine; LPV/r, lopinavir/ritonavir; NFV, nelfinavir; d4T, stavudine; CDC, Centers for Disease Control; DSMB, Data and Safety Monitoring Board.
doi:10.1371/journal.pmed.1001273.t001
step. Current guidelines [13] recommend that EID is undertaken at 4–6 weeks of age in infants born to mothers with HIV. However, most women do not know their HIV status, because of late or incomplete antenatal care and suboptimal access to HIV testing and PMTCT services [1]. Furthermore, HIV diagnosis in infants is more complex than in older children and adults, because it entails virological testing, which remains expensive, labour-intensive, and technically challenging compared to serological testing. Adoption of early treatment guidelines for young children will therefore only have impact if the entire PMTCT/infant care pathway is strengthened. With increased antenatal HIV testing and PMTCT ART coverage, the vast majority of paediatric infections could be prevented; however, even in this situation, those infants who do become infected will largely be born to women with unknown HIV status. For example, with 95% uptake of antenatal testing and 95% PMTCT ART coverage, there will be 2- to 3-fold more infants with HIV born to mothers with unknown HIV status; this rises to 15- to 20-fold if PMTCT ART coverage is only 50% [14].

Although early infant ART is cost-saving compared to deferred ART [15,16], the relative treatment cost per child is higher than for adults because of the current price of appropriate formulations and the need for lifelong treatment. Unfortunately, where there are competing demands for limited funds and resources, early treatment of infants with HIV is often therefore seen as a high-burden activity. Initiation of the youngest children on ART has lagged acceptably behind that of older children and adults because of the challenges of treatment at this age (Box 1).

### Box 1. Challenges in the Treatment of Infants and Young Children with HIV

- Virological testing is required to ascertain HIV infection status
- Identification of infected infants is frequently delayed
- Disease progression is rapid, with mortality peaking in the first few months of life
- No reliable markers to predict rapid disease progression
- Limited repertoire of antiretroviral drugs and drug formulations
- Liquid formulations expensive, unpalatable, and difficult to carry/store
- Pharmacokinetics variable, due to developing metabolic pathways
- Frequent adjustment in dosing is required due to rapid growth during infancy
- Need for strategic drug sequencing in the context of lifelong treatment
- Adherence is challenging, with reliance on caregivers to administer medication
- Risk of drug resistance due to high viral loads during infancy
- Potential long-term toxicity of treatment, as ART is started during a developmentally sensitive period of early life

### Which ART Should Be Started in Young Children?

The choice of first-line ART regimen for infants with HIV is frequently complicated by prior exposure to non-nucleoside reverse transcriptase inhibitor (NNRTI) drugs, commonly used in PMTCT programs. A single point mutation in the virus confers high-level resistance to nevirapine (NVP), which is a preferred first-line drug in young children due to its cost, tolerability, inclusion in fixed-dose combination (FDC) tablets, and ease of administration. The only viable alternative for infants and young children in LMIC is to use lopinavir/ritonavir (LPV/r), a protease inhibitor (PI), in place of NVP. The P1060 trial, undertaken in six African countries, compared first-line NVP-based or LPV/r-based ART in young children (<3 years of age) who either had (cohort 1) or had not (cohort 2) been exposed to sd-NVP prophylaxis (Table 1) [3,6].

Results from cohort 1 were consistent with prior observational data [17], with a higher rate of principally virological treatment failure among children starting a NVP- compared to a LPV/r-based regimen [5]. More surprisingly, children in cohort 2, who had not been exposed to sd-NVP as far as could reasonably be ascertained, and were nearly a year older, showed a similar difference in outcome between first-line regimens [6]. The reasons underlying this difference have been debated, but remain unclear.

### Should Guidelines on ART for Infants and Young Children Be Changed?

WHO guidelines were amended in 2010 following the P1060 cohort 1 results, to recommend LPV/r-based first-line regimens for children under 24 months with previous exposure to NNRTIs for PMTCT [13]. A NVP-based regimen remains the recommended first-line regimen for infants and young children without previous exposure to NNRTIs. What should policymakers do in light of new data from P1060 cohort 2? The findings appear compelling: a 2-fold increased risk of treatment failure if an infant’s first-line regimen contains NVP, rather than LPV/r, whether or not the child has previously been exposed to NVP for PMTCT. However, there are advantages and disadvantages to changing guidelines to recommend universal LPV/r-based ART in young children, and the issues discussed below need to be considered.

### Does the Evidence Support a Change in Policy?

The P1060 trial was a robust, timely, and well-conducted study, in a field where few randomized controlled trial data exist; the results were highly significant with no heterogeneity across the two cohorts. However, treatment failure was a composite endpoint; there were very few deaths and the difference between NNRTI and PI arms was mostly driven by virological failure and toxicity. The virological endpoint was also composite (Table 1) and relatively short-term (24 weeks); might longer follow-up have led to a different result? Results from P1060 contrast with longer-term data from other settings. Data from a European/US trial (PENPACT-1), which followed 266 children with HIV (of whom 68 were <3 years) randomized to first-line PI- or NNRTI-based ART for median 5 years [18], and data from an observational cohort of 437 European infants starting either PI- or NNRTI-based ART [19] and followed for median 5.9 years, both showed no significant difference in virological outcome between PI and NNRTI groups. In fact, in the European infant cohort, a four-drug regimen that included NVP and 3 NRTI drugs was associated with better virological suppression and CD4 recovery than a three-drug PI-based regimen [19]. However, findings from Europe and the US cannot necessarily be extrapolated to LMIC. The P1060 trial certainly recruited the most relevant population to address
the question of which first-line regimen to use in LMIC and it is unlikely that another trial will address this question. Randomized data from the ARROW trial (http://www.arrowtrial.org; ISRCTN 24791894), which closes this year, will help to inform whether an initial four-drug ART regimen is beneficial in young children.

**What Is the Feasibility of Starting Young Children on PI-Based Regimens?**

LPV/r, the only widely available PI, is more challenging to use in infants than is NVP. LPV/r is currently only available as a bitter-tasting liquid, which requires a cold chain for transport, or as a paediatric heat-stable tablet that cannot be crushed as it rapidly loses bioactivity [20]. LPV/r is generally less well tolerated than NVP and children tend to gain weight less well [3,5]. Recent reports have described cardiac toxicity and transient adrenal dysfunction in newborns [21,22]; however, the long-term toxicity of LPV/r-based regimens in children starting treatment very early is poorly documented. Although NVP has well described toxicity, characterized by rash, Stevens Johnson syndrome, and/or hepatotoxicity, permanent discontinuation of treatment in infants and young children due to side effects is uncommon [23].

LPV/r has the advantage of a higher genetic barrier to resistance than NVP. In the CHER trial, only 7/375 (2%) infants starting first-line LPV/r-containing ART switched to second-line regimens after median 4.8 years of follow-up [15]. Use of LPV/r may therefore obviate the need for viral load monitoring, especially since it is unclear which second-line regimen could feasibly be used in LMIC following treatment failure with LPV/r, as NNRTI-based regimens would be unlikely to be robust. Darunavir (another PI) retains activity after failure of LPV/r, but requires separate ritonavir boosting and has not been evaluated in young children because of animal toxicity data. Integrase inhibitors or newer NNRTI drugs may be suitable for second-line regimens in children, but are not yet available.

**What Would Be the Cost Implications?**

LPV/r-based regimens are approximately 3-fold more expensive than NVP-based regimens (Clinton Healthcare Access Initiative, unpublished data). This is a major consideration in the current context of limited resources and funding uncertainty for ART programs. However, use of a more expensive regimen can be cost-effective and appropriate economic evaluations should be undertaken. The OCTANE trial reported superior outcomes among NVP-exposed women who subsequently initiated a PI-based regimen, compared to an NNRTI-based regimen [24]. Despite a 12-fold increase in cost of an adult LPV/r regimen compared to a NVP regimen, first-line LPV/r was shown to be very cost-effective in women previously exposed to d-NVP [25].

It appears intuitive that changing guidelines to recommend universal LPV/r-based ART would increase the number of children starting LPV/r. However, in light of the current drive to eliminate new HIV infections in children [26], an increasing number of mothers and infants will access PMTCT interventions, which are primarily NNRTI-based. As PMTCT coverage increases, those infants who do become infected will be eligible to start LPV/r as a result of prior NNRTI exposure, and the additional proportion of infants starting LPV/r due to a change in guidelines will fall as PMTCT coverage increases.

**Treatment 2.0 and the Need for Equity**

The WHO-led “Treatment 2.0” strategy was developed to improve the efficiency and impact of HIV care and treatment programs in LMIC [27]. Because health care workers in lower-level facilities manage adults and children together, there is a strong justification for harmonization with adult treatment as much as possible. In this context, universal LPV/r-based first-line regimens may limit the decentralization of paediatric services that is critically needed to narrow the treatment gap between adults and children [1]. The roll-out of LPV/r-based first-line regimens for infants in South Africa, while logistically feasible in most areas, has highlighted the challenges in ensuring cold-chain delivery and establishing effective procurement and supply chains down to primary care settings.

**Better Antiretroviral Drugs Are Needed for Infants and Young Children**

Children with HIV in LMIC are a largely neglected population, particularly in terms of access to suitable formulations [28]. There is an urgent need to produce formulations of current drugs that are suitable for young children, particularly FDC tablets that can be dispersed or crushed and mixed with food or liquids (Box 2). The most widely prescribed NNRTI-based regimens are available as FDCs; however, there are currently no PI-based FDCs and, due to the formulation of LPV/r, full FDC regimens are extremely unlikely to be developed. Given the findings of the P1060 trials, development of better PI-based regimens is a high priority. The CHAPAS-2 trial (ISRCTN 01946535) is evaluating the pharmacokinetics and acceptability of a new heat-stable “sprinkle” formulation of LPV/r for young children. If this trial demonstrates acceptability and equivalence of sprinkles to existing formulations, then LPV/r would be much easier to use in young children.

**Alternative Approaches**

An alternative approach to long-term PI treatment, explored in the South African NEVEREST trial (Table 1), is to start all infants on LPV/r, and later substitute NVP [3,4]. Children changing to NVP in NEVEREST were more likely to maintain an undetectable viral load (<50 copies/mL) than those staying on LPV/r, perhaps because of better adherence to the more palatable NVP formulation. However, children changing to NVP were also more likely to have episodes of higher virological failure (>1,000 copies/mL) if they did fail, compared to those staying on LPV/r, likely because NVP has a low genetic barrier to resistance.

Would this strategy be practical for infants in LMIC? Virological monitoring before and after changing to NVP is not a realistic approach because access to viral load testing remains limited and costly. A simplified approach, using a fixed duration of LPV/r treatment in early infancy then switching to NVP once adherence becomes more challenging beyond infancy, is more practical to implement; however, this strategy still requires better and more affordable PI formulations to be feasible.

The current recommendation for universal, lifelong treatment may be difficult to sustain in LMIC because of cost, long-term toxicity, and eventual likelihood of virological failure. An alternative approach would be to start early ART during infancy, then stop therapy when risk of disease progression is lower. In CHER, around one-third of children who received early ART for 2 years and then stopped had no clinical or immunological indication to restart ART by the end of follow-up at around 5 years of age [15]. However, these children all started ART very early with high CD4 counts, and in a smaller Kenyan study in which infants started ART later, interruption appeared
Box 2. Requirements for Antiretroviral Drugs in Infants and Young Children

Suitable for use with tuberculosis treatment regimens

- Rifampicin causes drug interactions due to induction of hepatic cytochrome P450.
- Once-daily dosing
  - To improve adherence and reduce the risk of drug resistance
- Affordability
- Low toxicity
  - Avoid need for routine laboratory toxicity (biochemistry, haematology) monitoring
- Reduce switching to alternative regimens because of side effects
- Palatable, easy to carry, store, and administer
  - Fixed-dose combination tablets (scored, crushable, dispersible, chewable)
  - For PI regimens, heat-stable sprinkles which can be given with food
- No cold-chain requirements
- Easy to increase doses using weight bands as children grow
- Suitable formulation

much less feasible [29]. Nonetheless, there is a rationale for further exploring this approach in children, provided treatment interruption can be sufficiently long to deliver worthwhile reductions in toxicity and cost, and there is capacity to closely monitor children off ART.

Where to Next?

While elimination of childhood infection is the most important goal, it is unclear what will be achievable by 2015 [26]. Treatment guidelines will be revised for children with HIV in 2013; before then, it will be important to critically consider current and forthcoming data. Young children are already the most high-risk and neglected group affected by the HIV epidemic; only 23% of children in need of ART in LMIC were receiving treatment in 2010 [1]. Recommendations must therefore balance evidence with feasibility, and policymakers must continue to advocate a pipeline of appropriate paediatric antiretroviral drugs to enable evidence to be put into practice.

Author Contributions

Wrote the first draft of the manuscript: AP MP DMG. Contributed to the writing of the manuscript: PM VM EJA. ICMJE criteria for authorship read and met: AP MP MC PM VM EJA DMG. Agree with manuscript results and conclusions: AP MP MC PM VM EJA DMG.

References

1. World Health Organization, UNAIDS (2011) Global HIV/AIDS response: progress report 2011. Available: http://www.who.int/hivaids/en/resources/publications/2011/. Accessed 18 March 2012
2. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Guillet L, et al. (2004) Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 364: 1236–1243.
3. Coovadia A, Abrams EJ, Strehlau R, Meyers T, Martens L, et al. (2004) Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA 294: 1082–1090.
4. Kuhn L, Coovadia A, Abrams EJ, Strehlau R, Meyers T, Martens L, et al. (2012) Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis. Epub ahead of print 15 March 2012.
5. Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, et al. (2010) Antiretroviral treatment for children with perinatally nevirapine exposure. N Engl J Med 363: 1510–1520.
6. Palumbo P, Violari A, Lindsey J, Hughes M, Jean-Philippe P, et al. (2011) NVP vs LPV/r-based ART among HIV+ infants in resource-limited settings: the IMPAACT P1060 Trial. 10th Conference on Retroviruses and Opportunistic Infections; Boston, MA.
7. Prendergast A, Mphatswe W, Tudor-Williams G, Rakatani M, Pillay V, et al. (2000) Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants. AIDS 22: 1333–1343.
8. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, et al. (2000) Early antiretroviral therapy and mortality among HIV-infected infants. N Eng J Med 359: 2233–2244.
9. Penazzato M, Prendergast A, Tierny J, Cotton M, Gibb DM (2012) Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age. Cochrane Database Syst Rev. In press.
10. Berk DR, Falkovitz-Halpern MS, Hill DW, Albin C, Arieta A, et al. (2005) Temporal trends in early clinical manifestations of perinatal HIV infection in a population-based cohort. JAMA 295: 2221–2231.
11. Faye A, Le Chenadec J, Dollius C, Thuret I, Douard D, et al. (2004) Early versus deferred antiretroviral multitherapy in infants infected with HIV type 1. Clin Infect Dis 39: 1692–1698.
12. Luzuriaga K, McManus M, Fiscus S, Giaquinto C, et al. (2011) First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus lower viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis 11: 273–283.
13. Babiker A, Castro nee Green H, Compagnucci A, Fiscus S, Giaquinto C, et al. (2011) First-line antiretroviral treatment for children with perinatally acquired HIV type 1 infection in a population-based cohort. JAMA 295: 2221–2231.
14. Busscher PM, Mphatswe W, Rollins N (2011) Antiretroviral drugs in the cupboard are not enough: the impact of health systems’ performance on mother-to-child transmission of HIV. J Acquir Immune Defic Syndr 56: e45–e48.
15. Cotton M, Violari A, Gibb D, Otwombe K, Josipovic D, et al. Early ART followed by interruption is safe and is associated with better outcomes than deferred ART in HIV+ infants: final results from the 6-year randomized CHER trial, South Africa. 19th Conference on Retroviruses and Opportunistic Infections; 5–8 March 2012; Seattle, USA.
16. Meyer-Rath G, Violari A, Cotton M, Ndibongo B, Brennan A, et al. (2010) The cost of early vs. deferred paediatric antiretroviral treatment in South Africa - a comparative economic analysis of the first year of the CHER trial. XVIII International AIDS Conference; Vienna, Austria.
17. Lockman S, Shapiro RL, Smeaton LM, Wester C, Thor I, et al. (2007) Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Eng J Med 356: 134–147.
18. Babiker A, Castro nee Green H, Compagnucci A, Fiscus S, Giaquinto C, et al. (2011) First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus lower viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis 11: 273–283.
19. Judd A, The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCooed (2011) Early antiretroviral therapy in HIV-1 infected infants in Europe, 1990–2008: treatment response and duration of first line regimens. AIDS 25: 2279–2287.
20. Best BM, Capparelli EV, Dirp H, Rossi SS, Farrell MJ, et al. (2011) Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children. J Acquir Immune Defic Syndr 56: 385–391.
21. McArthur MA, Kaku SU, Fouks AL, Aly AM, Jain SK, et al. (2009) Twin preterm neonates with
cardiac toxicity related to lopinavir/ritonavir therapy. Pediatr Infect Dis J 28: 1127–1129.

22. Simon A, Warszawski J, Kariyawasam D, Le Chenadec J, Benhammou V, et al. (2011) Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers. JAMA 306: 70–78.

23. Mulenga V, Cook A, Walker AS, Kabamba D, Chijoka C, et al. (2010) Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination “baby pills” in Zambia: a randomized controlled trial. Clin Infect Dis 51: 1081–1089.

24. Lockman S, Hughes MD, McIntyre J, Zheng Y, Chipato T, et al. (2010) Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med 363: 1499–1509.

25. Ciaranello AL, Lockman S, Freedberg KA, Hughes M, Chu J, et al. (2011) First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. AIDS 25: 479–492.

26. UNAIDS (2011) Countdown To Zero: global plan towards elimination of new HIV infections among children by 2015 and keeping their mothers alive. Geneva: UNAIDS. Available: http://www.unaids.org/en/. Accessed 16 March 2012.

27. Lallemant M, Chang S, Cohen R, Pecoul B (2011) Pediatric HIV–a neglected disease? N Engl J Med 365: 501–503.

28. Wamalwa D, Benki-Nugent S, Langat A, Tapia K, Njugi E, et al. (2012) Treatment interruption in infants following 24 months of empiric ART: Kenya. 19th Conference on Retroviruses and Opportunistic Infections, 5–8 March 2012; Seattle, USA.